Wentworth Capital backs new $500 million biomed and innovation campus

July 14, 2023 Latest News BioPharma Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Private equity group Wentworth Capital will acquire a 99-year lease of the University of Sydney’s Medical Foundation Building, with plans to develop a dedicated $500 million life sciences campus facility. …

Subscribe now to continue reading.

Latest Video

‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma
November 24, 2025 - Latest News
New national report warns of deepening ovarian cancer burden and calls for urgent action
November 24, 2025 - Latest News
A scrapped website, almost $100 million, and the politics of what really matters
November 23, 2025 - Latest News
NSW Premier opens Australia’s first large-scale health translation hub at UNSW
November 24, 2025 - Latest News
Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions
November 24, 2025 - Latest News

Wentworth Capital backs new $500 million biomed and innovation campus

This is a preview of subscriber content

Latest Video

Most Read

‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma

New national report warns of deepening ovarian cancer burden and calls for urgent action

A scrapped website, almost $100 million, and the politics of what really matters

NSW Premier opens Australia’s first large-scale health translation hub at UNSW

Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions

New Stories

Slade Pharmacy marks anniversary with record research contributions at conferences

US Medicare sets reimbursement price for PromarkerD, paving way for major commercial rollout

Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model

Race Oncology secures human ethics approval for lung cancer trial of RC220

Syntara advances next-generation anti-fibrotic cream into Phase 1b trial

AdAlta chair says the company is 'on the cusp' of transformational growth

Scorecard reveals Australia is still ignoring its deadliest and most costly cancer

Sign In

Wentworth Capital backs new $500 million biomed and innovation campus

This is a preview of subscriber content

Latest Video

Most Read

‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma

New national report warns of deepening ovarian cancer burden and calls for urgent action

A scrapped website, almost $100 million, and the politics of what really matters

NSW Premier opens Australia’s first large-scale health translation hub at UNSW

Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions

Follow Us

New Stories

Slade Pharmacy marks anniversary with record research contributions at conferences

US Medicare sets reimbursement price for PromarkerD, paving way for major commercial rollout

Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model

Race Oncology secures human ethics approval for lung cancer trial of RC220

Syntara advances next-generation anti-fibrotic cream into Phase 1b trial

AdAlta chair says the company is 'on the cusp' of transformational growth

Scorecard reveals Australia is still ignoring its deadliest and most costly cancer